TITLE

Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G1 to S Phase

AUTHOR(S)
Murthy, Shalini; Wu, Min; Bai, V. Uma; Hou, Zizheng; Menon, Mani; Barrack, Evelyn R.; Kim, Sahn-Ho; Reddy, G. Prem-Veer
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The androgen receptor (AR) plays a critical role in the proliferation of prostate cancer cells. However, its mechanism of action in proliferation remains unknown. An understanding of the mechanism of AR action in proliferation may lead to the development of effective strategies for the treatment of prostate cancer. Methodology/Principal Findings: In this study we report that pulse treatment of synchronized LNCaP cells with Casodex, an AR-antagonist, for 4 hours in mid-G1 phase was sufficient to prevent cells from entering S phase. Since the assembly of pre-replication complex (pre-RC) in G1 is required for the progression of cells from G1 to S phase, the effect of Casodex during mid-G1 suggested that the role of AR in proliferation might be to regulate the assembly of pre-RC. To test this possibility, we investigated the interaction between AR and Cdc6, an essential component of pre-RC in LNCaP cells. AR co-localized and co-immunoprecipitated with Cdc6, and Casodex treatment disrupted this interaction. AR-immunoprecipitate (AR-IP) also contained cyclin E and cyclin A, which play a critical role in pre-RC assembly and cell cycle entry into S phase, and DNA polymerase-α, PCNA, and ribonucleotide reductase, which are essential for the initiation of DNA synthesis. In addition, in cells in S phase, AR co-sedimented with components of the DNA replication machinery of cells that entered S phase. Conclusions/Significance: Together, these observations suggest a novel role of AR as a component of the pre-RC to exert control over progression of LNCaP cells from G1 to S phase through a mechanism that is independent of its role as a transcription factor.
ACCESSION #
87624842

 

Related Articles

  • The expression and functional role of FOX transcription factor FOXJ1 in prostate cancer. Qi An; Dezhong Liu; Lian Zou // International Journal of Clinical & Experimental Medicine;2017, Vol. 10 Issue 1, p285 

    As one common malignant tumor in male reproductive-urinary system, the incidence of prostate cancer is increasing rapidly. Recent study revealed the participation of FOX transcription factor family in tumor occurrence and progression. FOXJ1, one member of FOX family, plays an important role in...

  • Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. Sen, Aritro; De Castro, Ismary; DeFranco, Donald B.; Deng, Fang-Ming; Melamed, Jonathan; Kapur, Payel; Raj, Ganesh V.; Rossi, Randall; Hammes, Stephen R. // Journal of Clinical Investigation;Jul2012, Vol. 122 Issue 7, p2469 

    In prostate cancer, the signals that drive cell proliferation change as tumors progress from castration-sensitive (androgen-dominant) to castration-resistant states. While the mechanisms underlying this change remain uncertain, characterization of common signaling components that regulate both...

  • Go forth and multiply. Robey, Rebecca // Nature Reviews Cancer;Jan2007, Vol. 7 Issue 1, p8 

    The article discusses the research by Colin Goding and colleagues on proliferation or metastasis of melanoma cells due to the microphthalmia-associated transcription factor (MITF). The ability of the melanoma cells to form tumors is hindered by the ectopic expression of MITF. The research...

  • EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells. PEIJIE CHEN; YAN HUANG; BO ZHANG; QIUQUAN WANG; PEIMING BAI // Oncology Letters;2014, Vol. 8 Issue 1, p41 

    numerous human cancers. However, to the best of our knowledge, the role that EphA2 plays in prostate cancer is not entirely clear. To investigate the roles of EphA2 in the development and progression of prostate cancer, the present study initially evaluated the roles of the EphA2 protein in...

  • The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. Kissick, Haydn T.; On, Seung T.; Dunn, Laura K.; Sanda, Martin G.; Asara, John M.; Pellegrini, Kathryn L.; Noel, Jonathan K.; Arredouani, Mohamed S. // BMC Cancer;Aug2015, Vol. 15 Issue 1, p1 

    Background: The TMPRSS2-ERG gene fusion occurs in about half of prostate cancer (PCa) cases and results in overexpression of the transcription factor ERG. Overexpression of ERG has many effects on cellular function. However, how these changes enhance cell growth and promote tumor development is...

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. Cabot, Richard C.; Harris, Nancy Lee; Rosenberg, Eric S.; Shepard, Jo-Anne O.; Cort, Alice M.; Ebeling, Sally H.; McDonald, Emily K.; Scher, Howard I.; Fizazi, Karim; Saad, Fred; Taplin, Mary-Ellen; Sternberg, Cora N.; Miller, Kurt; de Wit, Ronald; Mulders, Peter; Chi, Kim N.; Shore, Neal D.; Armstrong, Andrew J.; Flaig, Thomas W.; Fl�chon, Aude // New England Journal of Medicine;9/27/2012, Vol. 367 Issue 13, p1187 

    Background: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor�signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy....

  • La deprivazione androgenica nel carcinoma prostatico: evidenze cliniche e prospettive future. Pinto, F.; Calarco, A.; Totaro, A.; Sacco, E.; Volpe, A.; Racioppi, M.; D'Addessi, A.; Bassi, P. F. // Urologia;2010, Vol. 77 Issue 2, p71 

    Androgens are involved in the development and progression of prostate cancer even if the mechanism is not well-recognized. For this reason androgen-deprivation therapy remains a milestone for the treatment of patients with advanced and metastatic disease and, in the last years, in conjunction...

  • La deprivazione androgenica nel carcinoma prostatico: evidenze cliniche e prospettive future. Pinto, F.; Calarco, A.; Totaro, A.; Sacco, E.; Volpe, A.; Racioppi, M.; D'Addessi, A.; Bassi, P. F. // Urologia;2010, Vol. 77 Issue 2, p71 

    Androgens are involved in the development and progression of prostate cancer even if the mechanism is not well-recognized. For this reason androgen-deprivation therapy remains a milestone for the treatment of patients with advanced and metastatic disease and, in the last years, in conjunction...

  • The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Olson, Brian; Johnson, Laura; McNeel, Douglas // Cancer Immunology, Immunotherapy;Mar2013, Vol. 62 Issue 3, p585 

    The androgen receptor (AR) plays an essential role in the development and progression of prostate cancer. However, while it has long been the primary molecular target of metastatic prostate cancer therapies, it has not been explored as an immunotherapeutic target. In particular, the AR...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics